Can analysts adopt a bullish outlook for Exact Sciences Corporation (NASDAQ:EXAS)?

Exact Sciences Corporation (NASDAQ:EXAS) LogoInvestors sentiment decreased to 1.01 in Q2 2018. Its down 0.14, from 1.15 in 2018Q1. It turned negative, as 44 investors sold Exact Sciences Corporation shares while 97 reduced holdings. 62 funds opened positions while 80 raised stakes. 100.39 million shares or 1.50% less from 101.92 million shares in 2018Q1 were reported.
Cambridge Investment Research Inc accumulated 24,459 shares or 0.02% of the stock. Rmb Cap Ltd Liability invested in 15,822 shares or 0.02% of the stock. 419,551 are held by Tiaa Cref Invest Management Ltd Liability Co. Mackay Shields Ltd holds 0.01% or 35,161 shares. Prelude Management Ltd invested 0.13% in Exact Sciences Corporation (NASDAQ:EXAS). Captrust Advsrs has invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). The Texas-based Dimensional Fund Advsrs L P has invested 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Moreover, Employees Retirement Systems Of Ohio has 0.04% invested in Exact Sciences Corporation (NASDAQ:EXAS). 57,600 were accumulated by Td Asset Inc. Numerixs reported 0.26% in Exact Sciences Corporation (NASDAQ:EXAS). Hussman Strategic Advsrs Inc has invested 0.4% in Exact Sciences Corporation (NASDAQ:EXAS). Ubs Asset Americas reported 0% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% in Exact Sciences Corporation (NASDAQ:EXAS) or 7,674 shares. Putnam Invests Ltd Com invested in 0% or 22,223 shares. Cubist Systematic Strategies Limited Liability Corp holds 139,718 shares or 0.42% of its portfolio.

Since July 30, 2018, it had 0 insider buys, and 9 selling transactions for $13.56 million activity. Shares for $174,118 were sold by COWARD D SCOTT on Sunday, September 30. The insider Fallon John A. sold 2,373 shares worth $139,675. On Tuesday, August 28 the insider WYZGA MICHAEL S sold $184,730. Zanotti Katherine S had sold 2,847 shares worth $167,574. $77,577 worth of stock was sold by Doyle James Edward on Monday, July 30. Carey Thomas D. had sold 3,427 shares worth $201,713 on Monday, July 30.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 7 analysts covering Exact Sciences (NASDAQ:EXAS), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Exact Sciences had 13 analyst reports since June 15, 2018 according to SRatingsIntel. Robert W. Baird maintained it with “Outperform” rating and $70 target in Monday, July 9 report. Cowen & Co maintained Exact Sciences Corporation (NASDAQ:EXAS) on Monday, June 18 with “Buy” rating. Robert W. Baird maintained it with “Outperform” rating and $74 target in Thursday, August 23 report. On Friday, June 15 the stock rating was maintained by Canaccord Genuity with “Buy”. The rating was maintained by Canaccord Genuity on Wednesday, September 12 with “Buy”. The firm has “Outperform” rating by Robert W. Baird given on Tuesday, September 11. The firm earned “Buy” rating on Thursday, November 29 by UBS. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Thursday, September 6 by Bank of America. Bank of America maintained it with “Buy” rating and $75 target in Monday, July 23 report. The company was maintained on Thursday, August 2 by Bank of America. Below is a list of Exact Sciences Corporation (NASDAQ:EXAS) latest ratings and price target changes.

29/11/2018 Broker: UBS Rating: Buy New Target: $100.0000 Maintain
31/10/2018 Broker: Jefferies Old Rating: Buy New Rating: Buy Old Target: $74 New Target: $84 Maintain
12/09/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $72 New Target: $87 Maintain
11/09/2018 Broker: Robert W. Baird Old Rating: Outperform New Rating: Outperform Old Target: $74 New Target: $85 Maintain
06/09/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $68 New Target: $92 Maintain
23/08/2018 Broker: Robert W. Baird Old Rating: Outperform New Rating: Outperform Old Target: $65 New Target: $74 Maintain
02/08/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $75 New Target: $68 Maintain
02/08/2018 Broker: Jefferies Old Rating: Buy New Rating: Buy Old Target: $60 New Target: $57 Maintain
23/07/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $67 New Target: $75 Maintain
19/07/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $67 New Target: $76 Maintain

The stock decreased 1.34% or $1.02 during the last trading session, reaching $74.92. About 1.57 million shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 76.39% since December 7, 2017 and is uptrending. It has outperformed by 60.77% the S&P500.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $9.21 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

More notable recent Exact Sciences Corporation (NASDAQ:EXAS) news were published by: Benzinga.com which released: “Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO – Benzinga” on December 04, 2018, also Nasdaq.com with their article: “Noteworthy Wednesday Option Activity: EXAS, BG, DXC – Nasdaq” published on October 31, 2018, Benzinga.com published: “40 Biggest Movers From Yesterday – Benzinga” on November 29, 2018. More interesting news about Exact Sciences Corporation (NASDAQ:EXAS) were released by: Seekingalpha.com and their article: “Exact Sciences up 10% premarket after Q3 beat – Seeking Alpha” published on October 31, 2018 as well as Seekingalpha.com‘s news article titled: “Canaccord impressed with possible Cologuard competition – Seeking Alpha” with publication date: October 10, 2018.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.